首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Endovascular repair of thoracic aortic disease with the EndoFit stent-graft: short and midterm results from a single center.
【24h】

Endovascular repair of thoracic aortic disease with the EndoFit stent-graft: short and midterm results from a single center.

机译:EndoFit支架移植物对胸主动脉疾病进行血管内修复:单个中心的短期和中期结果。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To analyze the outcomes of endovascular treatment of thoracic aortic pathologies performed at a single center with the EndoFit thoracic stent-graft system. METHODS: From January 2002 to January 2007, 41 patients (33 men; mean age 69.3+/-9.7 years, range 48-84) were treated for thoracic aortic disease with the EndoFit stent-graft system. Patient data were retrieved from a retrospective review of hospital records. Indications for treatment were progression of aneurysm size in atherosclerotic aneurysms (n = 24, mean aneurysm diameter 7.19+/-1.48 cm), acute contained aortic rupture (n = 5), aortic dissection (n = 6), penetrating atherosclerotic ulcers (n = 4), post-traumatic pseudoaneurysm (n 1), and post coarctation repair aneurysm (n stent-graft was successfully deployed in all 41 patients. The in-hospital and 30-day mortality rate was 7.3% (3 patients). Three (7.3%) postoperative endoleaks were recorded: a proximal type Ia and a distal Ib both resolved spontaneously at 1 and 3 months, respectively. The third patient had a persistent type Ia endoleak; conversion was necessary after 1 year. There was only 1 case of spinal ischemia, with consequent lower extremity weakness; no paraplegia was observed. During a mean 24.8-month follow-up, 2 secondary type Ia endoleaks were treated with additional stent-grafts. There were 7 (17%) deaths during follow-up. At 2 years, overall patient survival by Kaplan-Meier analysis was 70%; aneurysm-related survival was 89%. CONCLUSION: Endovascular treatment of vascular disease involving the descending thoracic aorta can be safely performed with the EndoFit thoracic stent-graft system.
机译:目的:分析使用EndoFit胸腔支架移植系统在单个中心进行胸主动脉病变的血管内治疗的结果。方法:从2002年1月至2007年1月,采用EndoFit支架-移植系统治疗41例患者(33例男性,平均年龄69.3 +/- 9.7岁,范围48-84),治疗胸主动脉疾病。从回顾性的医院记录中检索患者数据。治疗的指征是动脉粥样硬化动脉瘤的大小进展(n = 24,平均动脉瘤直径7.19 +/- 1.48 cm),急性主动脉破裂(n = 5),主动脉夹层(n = 6),穿透性动脉粥样硬化性溃疡(n = 4),创伤后假性动脉瘤(n 1)和缩窄后修复动脉瘤(n支架植入物成功部署在所有41例患者中,住院和30天死亡率为7.3%(3例)。3记录有7.3%的术后内渗:近端Ia型和远端Ib分别在1个月和3个月时自发消退;第三例患者持续存在Ia型内渗; 1年后有必要进行转换,只有1例脊髓缺血,导致下肢无力;未观察到截瘫;在平均24.8个月的随访期间,对2例Ia型继发性内漏进行了额外的支架植入治疗,随访期间有7例(17%)死亡。2岁时,Kaplan的总体患者生存率-迈尔分析为70%;与动脉瘤相关的生存率为89%。结论:使用EndoFit胸腔支架植入系统可以安全地对涉及降主动脉的血管疾病进行血管内治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号